About: Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 1997 (uk) article scientifique publié en 1997 (fr) im September 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 1997 (ast) scientific article published on 01 September 1997 (en)
publication date	wds:Q73731733-7C663899-3BA9-414D-A823-BAD85F2543CA
publication date	1997-09-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73731733-AF57D757-5FCE-4883-A3A0-FE4549205EC8
language of work or name	English
cites work	wds:Q73731733-400D4BDD-77D7-4019-B201-E93C9AA036C4 wds:Q73731733-407380D6-D064-4478-981D-609671DC1058 wds:Q73731733-5B4C5FCC-9CBC-4876-A76B-255E32CB81AD wds:Q73731733-A6C3D6E9-67B4-46D0-A943-6204D436953A wds:Q73731733-AE6A69F4-6731-41E9-AB8E-EAA129D31D9E wds:Q73731733-DC759977-0AFA-442F-B829-48EFD7DF4F6F wds:Q73731733-EBADF3A6-5DA2-4850-BB97-CA213B587DD5 wds:Q73731733-EBFDF99F-B6A1-432B-A19B-9BF7F36C4017 wds:Q73731733-EDCC4992-481B-4D9B-A3A1-6F1B08336776 wds:Q73731733-F6BE62A7-A86E-41A6-86F3-AA73CDBDFFC4 wds:Q73731733-F98ECFDD-891F-434E-BD56-5EC0DC1515E0 wds:Q73731733-FECB510D-DA82-4E6A-BF03-9F4284201A78
cites work	Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase Specific regulation of gene expression by antisense, sense and antigene nucleic acids Pharmacokinetics of antisense oligonucleotides Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial Caco-2 cells. Antisense oligonucleotides as antiviral agents Tritium labeling of antisense oligonucleotides by exchange with tritiated water Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Quantitation of phosphorothioate oligonucleotides in human plasma Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides
author name string	wds:Q73731733-2ABD58FA-2B0B-46F1-B467-120002430939 wds:Q73731733-48AFAA72-6D20-47D7-A59D-8E7C968FCCA1 wds:Q73731733-68C0D7FD-A290-4065-AEA1-FC505230B7DA wds:Q73731733-95C62A8A-E4C4-43E4-AFB6-D6B34B7FF6F1 wds:Q73731733-97E02A33-F5B4-4212-97C7-F6B5CA8D2996 wds:Q73731733-9E7CF992-7CF1-491B-803D-E905230D6304
author name string	J A Phillips P L Nicklin D Bayley R A Christian R Geary S J Craig
rdfs:label	Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration (en) Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration (nl)
skos:prefLabel	Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration (en) Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration (nl)
name	Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration (en) Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration (nl)
title	wds:Q73731733-3728E1B6-70B4-47E6-AA5C-EBA280268397
title	Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration (en)
page(s)	wds:Q73731733-C88D2E50-9F21-4C07-AD08-9D5132A0EE2F
page(s)	657-668
instance of	wds:Q73731733-D0D3E9CA-45F4-4966-9140-2730BA5DB916
instance of	scholarly article
main subject	wds:Q73731733-F2BCA0F0-77A0-4525-B5F3-38182D557C37
main subject	pharmacokinetics
PubMed ID	wds:Q73731733-7D3967EB-B6F3-44C0-8828-27F175AC3984
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9310342
PubMed ID	9310342
published in	wds:Q73731733-3FAF0E77-6978-4BE4-8761-1D681CEBF4FC
published in	Biochemical Pharmacology
issue	wds:Q73731733-42F3EAA1-18DD-4611-9B82-129C215713AE
volume	wds:Q73731733-B03921AE-4EB4-4CEB-8683-F2FAA6D4F1B9
issue	6
volume	54
DOI	wds:Q73731733-FC1CA887-E22A-4DB5-8191-7C26EEAF53EC
DOI	http://dx.doi.org/10.1016/S0006-2952(97)00190-1
DOI	10.1016/S0006-2952(97)00190-1
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73731733
is cites work of	Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes Fomivirsen: clinical pharmacology and potential drug interactions Modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice Detection of a mixed-backbone oligonucleotide (GEM 231) in liver and tumor tissues by capillary electrophoresis Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection PET imaging of gene expression Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts Imaging gene expression: principles and assays Capillary electrophoresis in clinical and forensic analysis: recent advances and breakthrough to routine applications Blocking TLR7- and TLR9-mediated IFN-α production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Co-administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): a role for the scavenger receptor in its in vivo disposition Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys. Distribution of a 20-mer phosphorothioate oligonucleotide, CGP69846A (ISIS 5132), into airway leukocytes and epithelial cells following intratracheal delivery to brown-norway rats Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Pseudo-cyclic oligonucleotides: in vitro and in vivo properties RAB10: an Alzheimer's disease resilience locus and potential drug target Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221 Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects
is cites work of	wds:Q36086300-28F060F7-EF75-4E14-9943-2CBA868D44B8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software